Table 2.
Repeated-measures Bayesian statistical analysis of change from baseline in PASP (mmHg)
| Time point | Posterior median difference (SD) | 95% credible interval | Posterior probability of true difference (%) | |||
|---|---|---|---|---|---|---|
| < 0 | < − 2.5 | < − 3 | < − 5 | |||
| T1 | − 0.662 (2.193) | (− 5.037, 3.815) | 63.60 | 17.38 | 12.13 | 2.57 |
| T2 | − 2.796 (3.430) | (− 9.729, 4.027) | 81.26 | 53.83 | 47.39 | 24.11 |
| T3 | − 0.018 (4.145) | (− 8.475, 8.086) | 50.18 | 26.13 | 22.24 | 10.75 |
| T4 | − 0.291 (2.328) | (− 4.960, 4.386) | 55.59 | 15.28 | 10.82 | 2.42 |
mITT modified intent-to-treat, PASP pulmonary artery systolic pressure, SD standard deviation
Treatment comparisons between GSK2586881 and placebo in the mITT2 (Part 2) population are reported